^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium
Published date:
03/19/2021
Excerpt:
Ipatasertib (IPAT) is an orally administered selective protein kinase B (AKT) inhibitor…The human endometrioid EC cell lines ECC-1 (PTEN mutant) and HEC-1A (PTEN wild type, PIK3CA mutant, KRAS mutant)…PAT inhibited cellular proliferation in a dose dependent fashion in both cell lines after 72 hours of treatment. IPAT significantly inhibited cell proliferation and induced apoptosis...in human endometrioid EC cell lines.
